We are live on ! Find out more
OGEN icon

Oragenics
OGEN

11 hedge funds and large institutions have $8.16M invested in Oragenics in 2017 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more capital inflows, than outflows

Capital inflows: $79.3K | Capital outflows: $34K

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

0.08% less ownership

Funds ownership: 39.5% → 39.42% (-0.08%)

8% less funds holding

Funds holding: 12 → 11 (-1)

Holders
11
Holders Change
-1
Holders Change %
-8.33%
% of All Funds
0.27%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
2
Increased
–
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Bank of New York Mellon
Bank of New York Mellon
New York
+$72.7K
2
Virtu Financial
Virtu Financial
New York
+$6.61K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$18K
2
Goldman Sachs
Goldman Sachs
New York
-$14K
3
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance)
Ontario, Canada
-$2K

OGEN Hedge Fund Activity: Q3 2017 in Review

11 of the 4,023 institutional investors tracked by Wall St. Rank reported a position in Oragenics (OGEN) for Q3 2017, worth a combined $8.16M — up 13% from $7.2M a quarter earlier.

Fund positioning in OGEN was balanced in Q3 2017: 2 funds opened new positions, 2 closed out, 0 added to existing stakes and 0 trimmed.

The largest buyer was Bank of New York Mellon, opening a new position worth an estimated $72.7K. The largest seller was Citadel Advisors, exiting entirely with an estimated $18K sold.

  • 11 institutional investors held Oragenics (OGEN) as of Q3 2017, down from 12 in Q2 2017.
  • Funds reported $8.16M of Oragenics stock for Q3 2017, up 13% quarter-over-quarter.
  • 2 funds opened new Oragenics positions in Q3 2017 and 2 closed out, a net change of 0 holders.
  • The largest Oragenics buyer in Q3 2017 was Bank of New York Mellon, an estimated $72.7K added.
  • The largest Oragenics seller in Q3 2017 was Citadel Advisors, an estimated $18K sold.

Based on aggregated 13F filings for Q3 2017.